Pharmacokinetics and toxicity of sodium selenite in the treatment of patients with carcinoma in a phase I clinical trial: The SECAR study

Nutrients

Volumn 7, Issue 6, 2015, Pages 4978-4994

  Brodin, Ola ^a   Eksborg, Staffan ^b   Wallenberg, Marita ^b   Asker Hagelberg, Charlotte ^b,c   Larsen, Erik H ^d   Mohlkert, Dag ^a   Lenneby Helleday, Clara ^a   Jacobsson, Hans ^b   Linder, Stig ^e,f   Misra, Sougat ^b   Björnstedt, Mikael ^b  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c MEDICAL PRODUCTS AGENCY   (Sweden)

^d TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^e KAROLINSKA INSTITUTE   (Sweden)

^f LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Carcinoma; Maximum tolerated dose; Pharmacokinetics; Sodium selenite

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CREATININE; CYTOSTATIC AGENT; FLUORODEOXYGLUCOSE F 18; HEMOGLOBIN; LACTATE DEHYDROGENASE; SODIUM SELENITE; UREA; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CARCINOMA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; LEUKOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MUSCLE CRAMP; PHASE 1 CLINICAL TRIAL; SINGLE DRUG DOSE; THROMBOCYTE COUNT; TOXICITY; TREATMENT DURATION; TUMOR VOLUME; BIOASSAY; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; NAUSEA; NEOPLASMS; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOMARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENDPOINT DETERMINATION; FATIGUE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NAUSEA; NEOPLASMS; SODIUM SELENITE; TREATMENT OUTCOME;

EID: 84929347750     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu7064978     Document Type: Article

References (27)

1. Yan, L.; Spallholz, J.E. Generation of reactive oxygen species from the reaction of selenium compounds with thiols and mammary tumor cells. Biochem. Pharmacol. 1993, 45, 429-437.
2. Gorrini, C; Harris, IS.; Mak, T.W. Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 2013, 12, 931-947.
3. Trachootham, D.; Alexandre, J.; Huang, P. Targeting cancer cells by ros-mediated mechanisms: A radical therapeutic approach? Nat. Rev. Drug. Discov. 2009, 8, 579-591.
4. Luo, H; Yang, Y; Huang, F.; Li, F.; Jiang, Q.; Shi, K.; Xu, C. Selenite induces apoptosis in colorectal cancer cells via akt-mediated inhibition of β-catenin survival axis. Cancer Lett. 2012, 315, 78-85.
5. Jiang, Q.; Wang, Y.; Li, T.; Shi, K.; Li, Z.; Ma, Y.; Li, F.; Luo, H.; Yang, Y.; Xu, C. Heat shock protein 90-mediated inactivation of nuclear factor-κb switches autophagy to apoptosis through becn1 transcriptional inhibition in selenite-induced nb4 cells. Mol. Biol. Cell 2011, 22, 1167-1180.
6. Hoefig, C.S.; Renko, K.; Köhrle, J.; Birringer, M.; Schomburg, L. Comparison of different selenocompounds with respect to nutritional value vs. Toxicity using liver cells in culture. J. Nutr. Biochem. 2011, 22, 945-955.
7. Wallenberg, M.; Misra, S.; Wasik, A.M.; Marzano, C.; Bjornstedt, M.; Gandin, V.; Fernandes, A.P. Selenium induces a multi-targeted cell death process in addition to ros formation. J. Cell Mol. Med. 2014, 18, 671–684.
8. Fico, M.E.; Poirier, K.A.; Watrach, A.M.; Watrach, M.A.; Milner, J.A. Differential effects of selenium on normal and neoplastic canine mammary cells. Cancer Res. 1986, 46, 3384–3388.
9. Watrach, A.M.; Milner, J.A.; Watrach, M.A.; Poirier, K.A. Inhibition of human breast cancer cells by selenium. Cancer Lett. 1984, 25, 41–47.
10. Nilsonne, G.; Sun, X.; Nystrom, C.; Rundlof, A.K.; Fernandes, A.P.; Bjornstedt, M.; Dobra, K. Selenite induces apoptosis in sarcomatoid malignant mesothelioma cells through oxidative stress. Free Radical. Biol. Med. 2006, 41, 874–885.
11. Caffrey, P.B.; Frenkel, G.D. The development of drug resistance by tumor cells in vitro is accompanied by the development of sensitivity to selenite. Cancer Lett. 1994, 81, 59–65.
12. Caffrey, P.B.; Frenkel, G.D. Selenite cytotoxicity in drug resistant and non-resistant human ovarian tumor cells. Cancer Res. 1992, 52, 4812–4816.
13. Björkhem-Bergman, L.; Jönsson, K.; Eriksson, L.C.; Olsson, J.M.; Lehmann, S.; Paul, C.; Björnstedt, M. Drug-resistant human lung cancer cells are more sensitive to selenium cytotoxicity. Effects on thioredoxin reductase and glutathione reductase. Biochem. Pharmacol. 2002, 63, 1875–1884.
14. Caffrey, P.B.; Frenkel, G.D. Sensitivity of melphalan-resistant tumors to selenite in vivo. Cancer Lett. 1997, 121, 177–180.
15. Milner, J.A. Effect of selenium on virally induced and transplantable tumor models. Fed. Proc. 1985, 44, 2568–2572.
16. Ip, C.; Medina, D. Current concepts of selenium and mammary tumorigenesis. In Cellular and Molecular Biology of Mammary Cancer; Medina, D., Kidwell, W., Heppner, G., Anderson, E., Eds.; Springer US: New York, NY, USA, 1987; pp. 479–494.
17. Milner, J.A. Selenium and the transplantable tumor. J. Agric. Food Chem. 1984, 32, 436–442.
18. Novoselov, S.V.; Calvisi, D.F.; Labunskyy, V.M.; Factor, V.M.; Carlson, B.A.; Fomenko, D.E.; Moustafa, M.E.; Hatfield, D.L.; Gladyshev, V.N. Selenoprotein deficiency and high levels of selenium compounds can effectively inhibit hepatocarcinogenesis in transgenic mice. Oncogene 2005, 24, 8003–8011.
19. Watson-Williams, E. A preliminary note on the treatment of inoperable carcinoma with selenium. Br. Med. J. 1919, 2, 463–464.
20. Todd, A.T. The selenide treatment of cancer. Br. J. Surg. 1934, 21, 619–631.
21. Manzanares, W.; Biestro, A.; Torre, M.H.; Galusso, F.; Facchin, G.; Hardy, G. High-dose selenium reduces ventilator-associated pneumonia and illness severity in critically ill patients with systemic inflammation. Intensive Care Med. 2011, 37, 1120–1127.
22. Forceville, X.; Laviolle, B.; Annane, D.; Vitoux, D.; Bleichner, G.; Korach, J.M.; Cantais, E.; Georges, H.; Soubirou, J.L.; Combes, A. et al. Effects of high doses of selenium, as sodium selenite, in septic shock: A placebo-controlled, randomized, double-blind, phase ii study. Crit Care 2007, 11, R73.
23. Mosteller, R.D. Simplified calculation of body-surface area. N. Engl. J. Med. 1987, 317, 1098.
24. Olm, E.; Fernandes, A.P.; Hebert, C.; Rundlöf, A.-K.; Larsen, E.H.; Danielsson, O.; Björnstedt, M. Extracellular thiol-assisted selenium uptake dependent on the xc- cystine transporter explains the cancer-specific cytotoxicity of selenite. Proc. Natl. Acad. Sci. USA 2009, 106, 11400–11405.
25. Turan, B.; Koc, E.; Hotomaroglu, O.; Kiziltan, E.; Yildirim, S.; Demirel, E. Tissue and concentration-dependent effects of sodium selenite on muscle contraction. Biol. Trace Elem. Res. 1998, 62, 265–280.
26. Caffrey, P.B.; Frenkel, G.D. Prevention of carboplatin-induced resistance in human ovarian tumor xenografts by selenite. Anticancer Res. 2013, 33, 4249–4254.
27. De Haas, E.C.; di Pietro, A.; Simpson, K.L.; Meijer, C.; Suurmeijer, A.J.H.; Lancashire, L.J.; Cummings, J.; de Jong, S.; de Vries, E.G.E.; Dive, C. et al. Clinical evaluation of m30 and m65 elisa cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. Neoplasia 2008, 10, 1041–1048.